ArticleFrontiers in oncology2025
An interpretable clinical-radiomics-deep learning model based on magnetic resonance imaging for predicting postoperative Gleason grading in prostate cancer: a dual-center study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Advancements in artificial intelligence for cancer diagnosis and prognosis prediction: current applications and emerging opportunities.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and test an interpretable machine learning model that combines clinical data, radiomics, and deep learning features using different regions of interest (ROI) from magnetic resonance imaging (MRI) to predict postoperative Gleason grading in prostate cancer (PCa). Methods: A retrospective analysis was conducted on 96 PCa patients from the Third Hospital of Shanxi Medical University (training set) and 33 patients from Taiyuan Central Hospital (testing set) treated between August 2014 and July 2022. Clinical data, including prostate-specific antigen and MRI data, were collected. Tumor and whole-prostate ROIs were delineated on T Results: All combined models performed well in the test set (AUC ≥ 0.75), with the LightGBM model achieving the highest accuracy (0.848). SHAP analysis effectively illustrated the contribution of each feature. The CALC demonstrated good agreement between predicted probabilities and actual outcomes, and DCA further indicated that the models provided significant net benefits for clinical decision-making across various risk thresholds. Conclusion: This study developed and validated interpretable MRI-based machine learning models that combine clinical data with radiomics and deep learning features from different regions of interest, demonstrating good performance in predicting postoperative Gleason grading in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.